Shares of ResMed Inc. (NYSE:RMD) have been given a consensus recommendation of “Hold” by the thirteen brokerages that are currently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $72.25.

Several brokerages recently weighed in on RMD. Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a report on Friday, October 27th. BMO Capital Markets raised their target price on shares of ResMed from $70.00 to $74.00 and gave the company a “market perform” rating in a report on Friday, October 27th. Zacks Investment Research cut shares of ResMed from a “buy” rating to a “sell” rating in a report on Tuesday, October 24th. JPMorgan Chase & Co. raised their target price on shares of ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a report on Monday, October 30th. Finally, Barclays raised their target price on shares of ResMed from $68.00 to $70.00 and gave the company an “underweight” rating in a report on Friday, October 27th.

Shares of ResMed (NYSE RMD) traded up $1.95 on Friday, hitting $93.47. 748,347 shares of the stock traded hands, compared to its average volume of 864,629. The firm has a market capitalization of $13,080.00, a PE ratio of 32.30 and a beta of 0.92. ResMed has a 1-year low of $67.04 and a 1-year high of $104.78.

ResMed (NYSE:RMD) last issued its quarterly earnings results on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.22. The business had revenue of $601.27 million for the quarter, compared to analysts’ expectations of $583.77 million. ResMed had a net margin of 12.98% and a return on equity of 22.75%. The business’s quarterly revenue was up 13.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.73 earnings per share. sell-side analysts predict that ResMed will post 3.34 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Investors of record on Thursday, February 8th will be issued a $0.35 dividend. The ex-dividend date of this dividend is Wednesday, February 7th. This represents a $1.40 annualized dividend and a yield of 1.50%. ResMed’s dividend payout ratio (DPR) is 48.78%.

In other ResMed news, CFO Brett Sandercock sold 1,250 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $85.36, for a total value of $106,700.00. Following the transaction, the chief financial officer now directly owns 79,572 shares in the company, valued at $6,792,265.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James Hollingshead sold 7,019 shares of the stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $84.16, for a total transaction of $590,719.04. Following the completion of the transaction, the insider now owns 66,409 shares in the company, valued at $5,588,981.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 49,802 shares of company stock worth $4,824,727. 1.77% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC purchased a new position in ResMed in the third quarter valued at approximately $113,000. Calton & Associates Inc. purchased a new position in ResMed in the fourth quarter valued at approximately $115,000. Toronto Dominion Bank increased its stake in ResMed by 12.8% in the second quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock valued at $135,000 after purchasing an additional 197 shares during the last quarter. Conning Inc. purchased a new position in ResMed in the fourth quarter valued at approximately $203,000. Finally, Commerzbank Aktiengesellschaft FI purchased a new position in ResMed in the fourth quarter valued at approximately $206,000. Institutional investors own 61.47% of the company’s stock.

WARNING: “ResMed Inc. (RMD) Receives Consensus Rating of “Hold” from Analysts” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2018/02/14/resmed-inc-rmd-receives-consensus-rating-of-hold-from-analysts.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Analyst Recommendations for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.